A Phase II Open Label Study of the PI3 Kinase (PI-3) Inhibitor, SF1126, in Patients With Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Trial Profile

A Phase II Open Label Study of the PI3 Kinase (PI-3) Inhibitor, SF1126, in Patients With Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs SF 1126 (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 11 Aug 2016 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.
    • 11 Aug 2016 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top